Genomic dissection of hurthle cell carcinoma reveals a unique class of thyroid malignancy

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages

  Ganly, Ian ^a,b   Filho, Julio Ricarte ^a   Eng, Stephanie ^a   Ghossein, Ronald ^b   Morris, Luc G T ^a,b   Liang, Yupu ^a   Socci, Nicholas ^a   Kannan, Kasthuri ^a   Mo, Qianxing ^c   Fagin, James A ^a   Chan, Timothy A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Radiation Oncology ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AKT1 GENE; ARTICLE; BRAF GENE; CHROMOSOMAL INSTABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLICULAR THYROID CANCER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HRAS GENE; HUMAN; MALE; MAP2K1 GENE; MUTATIONAL ANALYSIS; NRAS GENE; ONCOGENE K RAS; PAPILLARY THYROID CANCER; PIK3CA GENE; POINT MUTATION; PRIORITY JOURNAL; RET GENE; SOMATIC MUTATION; THYROID CANCER; THYROID CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID PARAFOLLICULAR CELL CARCINOMA; TUMOR GENE; TUMOR INVASION;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; CARCINOMA; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEW YORK CITY; POINT MUTATION; TERTIARY CARE CENTERS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84877710820     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3539     Document Type: Article

References (44)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 58,856 cases of thyroid carcinoma treated in U.S., 1985-1995. Cancer. 1998;83:2638-2648.
2. Montone KT, Baloch ZW, LiVolsi VA. The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med. 2008; 132:1241-1250.
3. Ghossein RA, Hiltzik DH, Carlson DL, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006;106(8): 1669-1676.
4. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996;172:692-694.
5. Grossman RF, Clark OH. Hurthle cell carcinoma. Cancer Control. 1997;4:13-17.
6. Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer. 2003; 97:1186-1194.
7. Besic N, Vidergar-Kralj B, Frkovic-Grazio S, et al. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid. Thyroid. 2003;13:577-584.
8. Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hurthle cell tumors of the thyroid gland. Cancer. 1991;68:1944-1953.
9. Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg. 2004;28:1266-1270.
10. DeLellis RA, Lloyd RV, Heitz PU. World Health Organization Classification of Tumors. Pathology and Genetics: Tumors of Endocrine Organs. Lyon, France: IARC Press; 2004:69-72.
11. Maximo V, Sobrinho-Simoes M. Mitochondrial DNA 'common' deletion in Hürthle cell lesions of the thyroid. J Pathol. 2000;192: 561-562.
12. Máximo V, Botelho T, Capela J, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. 2005;92:1892-1898.
13. Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot spot. World J Surg. 2008; 32(5):722-728.
14. Musholt PB, Imkamp F, von Wasielewski R, Schmid KW, Musholt TJ. RET rearrangements in archival oxyphilic thyroid tumors:new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery. 2003;134:881-889.
15. Thyroid carcinomas (version 2012). In: Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed December 2012.
16. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885-4893.
17. Beimfohr C, Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer. 1999;Mar 15; 80(6):842-847.
18. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26(8):1016-1023.
19. Taylor BS, Barretina J, Socci ND, et al. Functional copy-number alterations in cancer. PLoS One. 2008;Sep 11;3(9):e3179.
20. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics. 2003;19(2):185-193.
21. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix Gene Chip probe level data. Nucleic Acids Res. 2003;31(4):e15.
22. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article 3.
23. Silver N, Best S, Jiang J, Lay S. Selection of housekeeping genes for gene expression studies inhuman reticulocytes using real-time PCR. BMC Mol Biol. 2006;7:33.
24. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia. 2007;9:443-454.
25. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid cancer. Proc Natl Acad Sci U S A. 2005;102(52): 19075-19080.
26. Giordano TJ, Au AY, Kuick R, et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res. 2006;12(7 Pt 1):1983-1993.
27. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9):5116-5121.
28. DeGellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662-669.
29. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50(4):529-535.
30. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science. 2000;289(5483):1357-1360.
31. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439: 353-357.
32. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRaf mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63:1454-1457.
33. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinoma of the thyroid: a metanalysis. Cancer. 2007;110:38-46.
34. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTCrearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
35. Talini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent chromosomal imbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridisation. Lab Invest. 1999;79:547-555.
36. Singh B, Lim D, Cigudosa JC, et al. Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Surgery. 2000;128:888-894.
37. Wreesmann VB, Sleczka EM, Socci ND, et al. Genome wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res. 2004;64:3780-3789.
38. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H. DNA copy number changes in thyroid cancer. Am J Pathol. 1999;154: 1539-1547.
39. Frisk T, Kytola S, Wallin G, Zedenius J, Larsson C. Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. Genes Chromosomes Cancer. 1999;25:349-353.
40. Ciampo R, Zhu Z, Nikiforov YE. BRAF copy number gains in thyroid tumors detected by fluorescence in siti hybridisation. Endocr Pathol. 2005;16:99-105.
41. Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
42. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905.
43. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59:1811-1815.
44. Suzuki H, Masuda N, Shimura T, et al. Nuclear β-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res. 2008;28(3B):1821-1830.